The European Union's health regulator on Friday backed AstraZeneca and Daiichi Sankyo's drug Enhertu as a breast cancer ...
Enhertu improved overall survival versus chemotherapy in HER2-positive metastatic gastric cancer, prompting an interim ...
15h
GlobalData on MSNDaiichi Sankyo and AstraZeneca’s Enhertu shows OS improvements in Phase III trialDaiichi Sankyo and AstraZeneca’s Enhertu (trastuzumab deruxtecan) has shown clinically meaningful 'improvement' in the ...
The partners are pushing to expand Enhertu’s list of indications beyond its standing uses in breast, lung and gastric cancers ...
Enhertu already has seven FDA approvals across breast cancer, gastric cancer, non-small cell lung cancer (NSCLC), and ...
AstraZeneca and Daiichi Sankyo's Enhertu has become the first HER2-directed drug to mount a patient survival benefit in a ...
Cambridge: AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) has been recommended for approval in the ...
Dr. Debu Tripathy breaks down the FDA approval of Enhertu in unresectable or metastatic HR-positive, HER2-low or -ultralow ...
ADCs are currently at the forefront of cancer treatment, but persistent drug development challenges call for a new approach.
The global breast cancer drugs market size was valued at USD 34.25 billion in 2024 and is projected to reach from USD 37.30 ...
TOKYO & MUNICH - Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/Nasdaq: NASDAQ:AZN) have announced that their drug ENHERTU (trastuzumab deruxtecan) has been recommended for approval in the ...
European life sciences venture capital company Sofinnova Partners has raised €1.2 billion ($1.27 billion) in new funding that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results